Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection.
about
Multi-country estimate of different manifestations of aspergillosis in cystic fibrosisMultidrug resistance: an emerging crisisAntifungal susceptibility testing: current role from the clinical laboratory perspectiveAspergillus fumigatus in the cystic fibrosis lung: pros and cons of azole therapyProposal for a unified nomenclature for target-site mutations associated with resistance to fungicidesFungal cytochrome P450 sterol 14α-demethylase (CYP51) and azole resistance in plant and human pathogens.Modulation of Alternaria infectoria cell wall chitin and glucan synthesis by cell wall synthase inhibitors.Antifungal susceptibilities of Candida, Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010-2012).First detection of TR46/Y121F/T289A and TR34/L98H alterations in Aspergillus fumigatus isolates from azole-naive patients in Denmark despite negative findings in the environment.Myeloid derived hypoxia inducible factor 1-alpha is required for protection against pulmonary Aspergillus fumigatus infectionPractice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Clonal expansion and emergence of environmental multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR₃₄/L98H mutations in the cyp51A gene in India.Whole-genome comparison of Aspergillus fumigatus strains serially isolated from patients with aspergillosis.Aspergillus species and other molds in respiratory samples from patients with cystic fibrosis: a laboratory-based study with focus on Aspergillus fumigatus azole resistance.Incidence of Cyp51 A key mutations in Aspergillus fumigatus-a study on primary clinical samples of immunocompromised patients in the period of 1995-2013Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature.Genomic Context of Azole Resistance Mutations in Aspergillus fumigatus Determined Using Whole-Genome SequencingHigh prevalence of azole-resistant Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole.Multiple cyp51A-based mechanisms identified in azole-resistant isolates of Aspergillus fumigatus from China.Azole preexposure affects the Aspergillus fumigatus population in patients.Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosisEchinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geogrHypoxia enhances innate immune activation to Aspergillus fumigatus through cell wall modulation.Impact of in vivo triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: enhanced efficacy against Cyp51 mutant isolatesIn vitro susceptibility of Aspergillus fumigatus to isavuconazole: correlation with itraconazole, voriconazole, and posaconazole.Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus.Azole resistance in Aspergillus fumigatus from bronchoalveolar lavage fluid samples of patients with chronic diseases.Epidemiology and antifungal resistance in invasive Aspergillosis according to primary disease: review of the literature.Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics.ECIL-3 classical diagnostic procedures for the diagnosis of invasive fungal diseases in patients with leukaemia.Echinocandins: production and applications.Exploring azole antifungal drug resistance in Aspergillus fumigatus with special reference to resistance mechanisms.Multi-resistant aspergillosis due to cryptic species.Mechanisms of Antifungal Drug Resistance.Evaluation of mRNA Expression Levels of cyp51A and mdr1, Candidate Genes for Voriconazole Resistance in Aspergillus flavus.Medically important fungi respond to azole drugs: an update.Epidemiology and molecular mechanisms of antifungal resistance in Candida and Aspergillus.In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods.Interrogation of related clinical pan-azole-resistant Aspergillus fumigatus strains: G138C, Y431C, and G434C single nucleotide polymorphisms in cyp51A, upregulation of cyp51A, and integration and activation of transposon Atf1 in the cyp51A promoterDiagnostic of Fungal Infections Related to Biofilms.
P2860
Q21132028-C68D7779-E6CD-4A45-AB9E-0255AE62EA49Q21284693-E4C995D5-A87B-4F9E-A944-F3285BD108FFQ26862478-14D753C1-2903-4786-861B-267F8933CDF6Q28074671-FBF580EE-4BBB-4DB8-97C6-ED1801ACCB9EQ28822246-332324C8-E44F-497B-9B81-AF276D021D8BQ30318077-53550CB9-9D6C-4D1D-8938-7E4A7E2020EAQ30576509-A3D20416-B45C-462A-8AA1-2FE363A70FEFQ30938136-F51294F4-ECD4-4F9C-96E2-0D12E87B4998Q34057414-7E1F9045-42A5-4823-BA96-10B69DC4A5DFQ34257883-224475F1-CCD6-4938-8A14-8BFC65BC71B4Q34532546-FBC93668-2FD5-4D5E-9D6B-4AEB0A903C4CQ34534761-5BD8D761-ABF9-49C6-9323-5442C83ED6A6Q35036194-3DAE1BA5-021A-4CCC-906F-4D7F505B64BDQ35066763-0F8853C6-5E2A-4908-9828-D1F2AA1477E3Q35215022-F74FF06E-5EC9-47FC-B676-4DD052B64AC7Q35666591-8E0B4C0C-A521-4970-AA41-E48CC323295BQ35676292-4126AA92-A4E7-4281-BB71-D8DD5FC1D397Q35689428-4B2BDA76-2978-41FE-AF3B-9AA417E7048FQ35746043-B6F6B9C3-6D1C-4F42-82AD-FAAB3B964F19Q36172445-9BE69ACB-9D2E-4CE8-A98B-A7FF240295B9Q36505539-E3A17EB0-EA3A-4D73-9E09-67C31BDA4CF2Q37036246-025DA0C4-43B1-4EA1-BA49-945929CBF5E3Q37045301-2CC1E5CC-98B7-42A8-A546-2E5B5154BACCQ37263430-41DC67C4-3799-4A8D-A523-C281BB24CDE9Q37263445-24ED3451-88AA-49B9-BA65-0BBFA87A5C70Q37335649-5CA957A1-6E7B-4C0D-957E-0CB028933DF5Q37603643-804233A6-6E29-46D0-A7BA-98ADC971A17CQ37864427-0249A41F-DDA2-485B-825F-A2915D6D80CCQ37904672-219B5C8E-D4D4-456D-B9F9-18F7B472A6BFQ37974519-D32C7DD9-5DB3-4077-89A5-70DC26D4D1FFQ38086769-CBA2788B-8671-451F-9B6E-15BE0C3168A3Q38222570-F4D35BD3-0F0E-4CEE-A865-88B766055CB1Q38223608-1086C2DC-F13D-474D-B19A-A24634D372EAQ38266675-8E875EF8-C1C0-4E45-9C17-FA1C064D1732Q38282758-01512453-56DF-4B5D-9BF1-70ADBE3BBFF0Q38559208-AB8E3F88-7DDE-4DEB-B0B7-660D35034A2BQ38711698-F09BF6B1-E856-480F-B707-F37ACB80EC93Q38725931-AB96A125-FDDD-4CE0-BDF0-C9995D0A4360Q38726518-CECC9113-146E-4405-BB50-71F69C653A58Q38853348-3F9A8C2C-CAB5-4FDA-8B6F-0F33D4C8043B
P2860
Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 August 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection.
@en
Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection.
@nl
type
label
Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection.
@en
Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection.
@nl
prefLabel
Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection.
@en
Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection.
@nl
P2860
P921
P1433
P1476
Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection
@en
P2093
Maiken Cavling Arendrup
Susan Julie Howard
P2860
P356
10.3109/13693786.2010.508469
P478
49 Suppl 1
P577
2010-08-26T00:00:00Z